

# Sudipto Mukherjee

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6379350/sudipto-mukherjee-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

423  
citations

12  
h-index

19  
g-index

52  
ext. papers

638  
ext. citations

3.5  
avg, IF

3.23  
L-index

#	Paper	IF	Citations
49	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , <b>2018</b> , 132, 2115-2124	2.2	127
48	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. <i>Nature Communications</i> , <b>2019</b> , 10, 5386	17.4	29
47	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 4	7	21
46	Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, e463-e468	2	18
45	More is better: combination therapies for myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , <b>2015</b> , 28, 22-31	4.2	17
44	Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt462	9.7	17
43	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , <b>2016</b> , 128, 216-216	2.2	16
42	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , <b>2019</b> , 3, 4228-4237	7.8	16
41	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , <b>2020</b> , 34, 957-962	10.7	16
40	Therapy-related myelodysplastic syndromes, or are they?. <i>Blood Reviews</i> , <b>2017</b> , 31, 119-128	11.1	14
39	Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase. <i>Current Hematologic Malignancy Reports</i> , <b>2016</b> , 11, 86-93	4.4	14
38	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3737-3746	2.2	14
37	The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. <i>Oncologist</i> , <b>2017</b> , 22, 379-385	5.7	12
36	Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2536-42	1.9	12
35	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , <b>2020</b> , 105, e98-e101	6.6	10
34	Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 412-20	4.7	9
33	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1553-1561	7.1	9

32	and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1587-1590	1.9	9
31	A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence. <i>Blood</i> , <b>2019</b> , 134, 2091-2091	2.2	8
30	Novel Therapies in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , <b>2019</b> , 35, 150955	3.7	6
29	Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2016</b> , 16, 275-84	2.2	4
28	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 489-95	2	4
27	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 363-371	1.9	3
26	Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms. <i>Blood</i> , <b>2019</b> , 134, 4238-4238	2.2	2
25	A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes. <i>Blood</i> , <b>2020</b> , 136, 33-35	2.2	2
24	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 735-738	1.9	2
23	A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. <i>Blood Advances</i> , <b>2021</b> , 5, 4361-4369	7.8	2
22	Is the cure the poison? The evolving story of therapy-related myeloid malignancies. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 839-40	1.9	1
21	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1943-1953	1.9	1
20	Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1-2	4.7	1
19	A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 13-14	2.2	1
18	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , <b>2018</b> , 132, 4806-4806	2.2	1
17	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2696-2696	2.2	1
16	Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	1
15	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11047-11047	2.2	1

14	Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy. <i>Blood Advances</i> , <b>2021</b> ,	7.8	1
13	A case of hypereosinophilic syndrome with STAT5b N642H mutation. <i>Oxford Medical Case Reports</i> , <b>2021</b> , 2021, omaa129	0.6	1
12	A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 715-716	4.7	0
11	Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1532-1532	2.2	0
10	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 917.e1-917.e9		0
9	Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2020</b> , 136, 54-55	2.2	
8	A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients. <i>Blood</i> , <b>2020</b> , 136, 11-11	2.2	
7	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 2075-2075	2.2	
6	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 1527-1527	2.2	
5	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , <b>2018</b> , 132, 371-371	2.2	
4	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. <i>Blood</i> , <b>2019</b> , 134, 2595-2595	2.2	
3	Molecular dissection of normal karyotype acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7534-7534	2.2	
2	Disparities in receipt of complete diagnostic evaluation to confirm myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7555-7555	2.2	
1	Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2011</b> , 118, 120-120	2.2	